GRAIL, Inc. Hits Day Low of $41.50 Amid Price Pressure

GRAIL, Inc., a small-cap player in the Pharmaceuticals & Biotechnology sector, has experienced significant volatility today, hitting an intraday low of USD 41.50. The stock has seen a notable decline of 57.62% as of February 23, 2026, reflecting a challenging performance landscape. Over the past day, GRAIL's stock has dropped by 14.3%, contrasting sharply with the S&P 500's modest gain of 0.69%. In the past week, GRAIL's performance has been particularly stark, with a decrease of 55.87%, while the S&P 500 has risen by 1.07%. The one-month performance shows a decline of 58.98%, again underperforming the broader market, which has gained 1.66%. Year-to-date, GRAIL has faced a downturn of 49.73%, compared to the S&P 500's slight increase of 0.94%. Despite these challenges, GRAIL reported a 20.45% growth in net sales in January, indicating some positive operational metrics. However, the stock's high institutional holdings at 93.34% suggest a cautious approach among larger investors, as they have increased their stake by 6.57% in the previous quarter.